SCHEMBL4830401

SCHEMBL4830401

CCOC(=O)C(C)(C)Oc1ccc(SC(CC)c2sc(-c3ccc(C(F)(F)F)cc3)nc2C)cc1C

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 20/20 0.73
PPARA Q07869 5/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831819 0.92 PPARD (0.78) PPARDPPARA
SCHEMBL4831713 0.91 PPARD (0.60) PPARDPPARA
SCHEMBL4831880 0.84 PPARD (0.53) PPARDPPARA
SCHEMBL4822813 0.84 PPARD (0.53) PPARDPPARA
SCHEMBL4826090 0.84 PPARD (0.53) PPARDPPARA
SCHEMBL4830243 0.83 PPARD (0.53) PPARDPPARA
SCHEMBL4830364 0.83 PPARD (0.51) PPARDPPARA
SCHEMBL4826471 0.83 PPARD (0.51) PPARDPPARA
SCHEMBL4826476 0.83 PPARD (0.51) PPARDPPARA
SCHEMBL7101582 0.82 PPARD (0.59) PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343773-B1 THIAZOLE DERIVATIVES FOR TRAEING PPAR RELATED DISORDERS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP claimed
US-7105551-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 US claimed
US-20040063964-A1 Thiazole derivatives for treating ppar related disorders SMITHKLINE BEECHAM CORPORATION 2004-04-01 US claimed
EP-1343773-A1 THIAZOLE DERIVATIVES FOR TRAEING PPAR RELATED DISORDERS GLAXO GROUP LIMITED (GB) 2003-09-17 EP claimed
WO-2002062774-A1 THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS GLAXO GROUP LIMITED (GB) 2002-08-15 WO claimed
US-7439259-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2008-10-21 US disclosed
US-7439259-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2008-10-21 US disclosed
US-7439259-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2008-10-21 US disclosed
US-20060276519-A1 THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS CADILLA RODOLFO 2006-12-07 US disclosed
EP-1343773-B1 THIAZOLE DERIVATIVES FOR TRAEING PPAR RELATED DISORDERS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-7105551-B2 Thiazole derivatives for treating PPAR related disorders SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 US disclosed
US-20040063964-A1 Thiazole derivatives for treating ppar related disorders SMITHKLINE BEECHAM CORPORATION 2004-04-01 US disclosed
EP-1343773-A1 THIAZOLE DERIVATIVES FOR TRAEING PPAR RELATED DISORDERS GLAXO GROUP LIMITED (GB) 2003-09-17 EP disclosed
WO-2002062774-A1 THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS GLAXO GROUP LIMITED (GB) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276519-A1 THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885
US-20040063964-A1 Thiazole derivatives for treating ppar related disorders PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.